Superior Cuproptotic Efficacy of Diethyldithiocarbamate-CuO Nanoparticles over Diethyldithiocarbamate-CuO Nanoparticles in Metastatic Hepatocellular Carcinoma

Overview

Journal Front Pharmacol

Date 2024 Jul 30

PMID 39076585

Authors

Marwa M Abu-Serie

Assem Barakat

Sherif Ramadan

Noha Hassan Habashy

Affiliations

Soon will be listed here.

Abstract

Metastatic hepatocellular carcinoma (HC) is a serious health concern. The stemness of cancer stem cells (CSCs) is a key driver for HC tumorigenesis, apoptotic resistance, and metastasis, and functional mitochondria are critical for its maintenance. Cuproptosis is Cu-dependent non-apoptotic pathway (mitochondrial dysfunction) via inactivating mitochondrial enzymes (pyruvate dehydrogenase "PDH" and succinate dehydrogenase "SDH"). To effectively treat metastatic HC, it is necessary to induce selective cuproptosis (for halting cancer stemness genes) with selective oxidative imbalance (for increasing cell susceptibility to cuproptosis and inducing non-CSCs death). Herein, two types of Cu oxide nanoparticles (CuO "C(I + II)" NPs and CuO "C(I)" NPs) were used in combination with diethyldithiocarbamate (DD, an aldehyde dehydrogenase "ALDH" inhibitor) for comparative anti-HC investigation. DC(I + II) NPs exhibited higher cytotoxicity, mitochondrial membrane potential, and anti-migration impact than DC(I) NPs in the treated human HC cells (HepG2 and/or Huh7). Moreover, DC(I + II) NPs were more effective than DC(I) NPs in the treatment of HC mouse groups. This was mediated via higher selective accumulation of DC(I + II) NPs in only tumor tissues and oxidant activity, causing stronger selective inhibition of mitochondrial enzymes (PDH, SDH, and ALDH2) than DC(I)NPs. This effect resulted in more suppression of tumor and metastasis markers as well as stemness gene expressions in DC(I + II) NPs-treated HC mice. In addition, both nanocomplexes normalized liver function and hematological parameters. The computational analysis found that DC(I + II) showed higher binding affinity to most of the tested enzymes. Accordingly, DC(I + II) NPs represent a highly effective therapeutic formulation compared to DC(I) NPs for metastatic HC.

Citing Articles

Advances in non-apoptotic regulated cell death: implications for malignant tumor treatment.

Zhang Y, Yi S, Luan M Front Oncol. 2025; 15:1519119.

PMID: 39949740 PMC: 11821507. DOI: 10.3389/fonc.2025.1519119.

Ferroptosis- and stemness inhibition-mediated therapeutic potency of ferrous oxide nanoparticles-diethyldithiocarbamate using a co-spheroid 3D model of pancreatic cancer.

Abu-Serie M, Gutierrez-Garcia A, Enman M, Vaish U, Fatima H, Dudeja V J Gastroenterol. 2025; .

PMID: 39888413 DOI: 10.1007/s00535-025-02213-3.

References

Niitsu Y, Sato Y, Takayama T . Implications of glutathione-S transferase P1 in MAPK signaling as a CRAF chaperone: In memory of Dr. Irving Listowsky. Proc Jpn Acad Ser B Phys Biol Sci. 2022; 98(2):72-86. PMC: 8890996. DOI: 10.2183/pjab.98.005. View

Cui J, Li G, Yin J, Li L, Tan Y, Wei H . GSTP1 and cancer: Expression, methylation, polymorphisms and signaling (Review). Int J Oncol. 2020; 56(4):867-878. DOI: 10.3892/ijo.2020.4979. View

Muramatsu M, Sakai M . Mechanisms of a tumor marker, glutathione transferase P, expression during hepatocarcinogenesis of the rat. Proc Jpn Acad Ser B Phys Biol Sci. 2015; 82(9):339-52. PMC: 4338839. DOI: 10.2183/pjab.82.339. View

Margalef P, Kotsantis P, Borel V, Bellelli R, Panier S, Boulton S . Stabilization of Reversed Replication Forks by Telomerase Drives Telomere Catastrophe. Cell. 2018; 172(3):439-453.e14. PMC: 5786504. DOI: 10.1016/j.cell.2017.11.047. View

Yan Y, Zhang D, Zhou P, Li B, Huang S . HDOCK: a web server for protein-protein and protein-DNA/RNA docking based on a hybrid strategy. Nucleic Acids Res. 2017; 45(W1):W365-W373. PMC: 5793843. DOI: 10.1093/nar/gkx407. View

Tang D, Chen X, Kroemer G . Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res. 2022; 32(5):417-418. PMC: 9061796. DOI: 10.1038/s41422-022-00653-7. View

Josan S, Xu T, Yen Y, Hurd R, Ferreira J, Chen C . In vivo measurement of aldehyde dehydrogenase-2 activity in rat liver ethanol model using dynamic MRSI of hyperpolarized [1-(13) C]pyruvate. NMR Biomed. 2012; 26(6):607-12. PMC: 3634870. DOI: 10.1002/nbm.2897. View

Han J, Liu L, Yue X, Chang J, Shi W, Hua Y . A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts. Toxicol Appl Pharmacol. 2013; 273(3):477-83. DOI: 10.1016/j.taap.2013.09.009. View

Chen L, Wu M, Ji C, Yuan M, Liu C, Yin Q . Silencing transcription factor FOXM1 represses proliferation, migration, and invasion while inducing apoptosis of liver cancer stem cells by regulating the expression of ALDH2. IUBMB Life. 2019; 72(2):285-295. DOI: 10.1002/iub.2166. View

10.

Lv H, Liu X, Zeng X, Liu Y, Zhang C, Zhang Q . Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma. Front Pharmacol. 2022; 13:930041. PMC: 9273972. DOI: 10.3389/fphar.2022.930041. View

11.

Cvek B, Milacic V, Taraba J, Dou Q . Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells. J Med Chem. 2008; 51(20):6256-8. PMC: 2574941. DOI: 10.1021/jm8007807. View

12.

Munujos P, Coll-Canti J, Gella F . Assay of succinate dehydrogenase activity by a colorimetric-continuous method using iodonitrotetrazolium chloride as electron acceptor. Anal Biochem. 1993; 212(2):506-9. DOI: 10.1006/abio.1993.1360. View

13.

Abu-Serie M, Osuka S, Heikal L, Teleb M, Barakat A, Dudeja V . Diethyldithiocarbamate-ferrous oxide nanoparticles inhibit human and mouse glioblastoma stemness: aldehyde dehydrogenase 1A1 suppression and ferroptosis induction. Front Pharmacol. 2024; 15:1363511. PMC: 11076782. DOI: 10.3389/fphar.2024.1363511. View

14.

Kang X, Jadhav S, Annaji M, Huang C, Amin R, Shen J . Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems. Pharmaceutics. 2023; 15(6). PMC: 10302862. DOI: 10.3390/pharmaceutics15061567. View

15.

Satoh K, Itoh K, Yamamoto M, Tanaka M, Hayakari M, Ookawa K . Nrf2 transactivator-independent GSTP1-1 expression in "GSTP1-1 positive" single cells inducible in female mouse liver by DEN: a preneoplastic character of possible initiated cells. Carcinogenesis. 2002; 23(3):457-62. DOI: 10.1093/carcin/23.3.457. View

16.

Vallieres C, Holland S, Avery S . Mitochondrial Ferredoxin Determines Vulnerability of Cells to Copper Excess. Cell Chem Biol. 2017; 24(10):1228-1237.e3. PMC: 5654725. DOI: 10.1016/j.chembiol.2017.08.005. View

17.

Frohlich E . The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine. 2012; 7:5577-91. PMC: 3493258. DOI: 10.2147/IJN.S36111. View

18.

Li W, Liu K, Chen Y, Zhu M, Li M . Role of Alpha-Fetoprotein in Hepatocellular Carcinoma Drug Resistance. Curr Med Chem. 2020; 28(6):1126-1142. DOI: 10.2174/0929867327999200729151247. View

19.

Paul V, Lill R . Biogenesis of cytosolic and nuclear iron-sulfur proteins and their role in genome stability. Biochim Biophys Acta. 2015; 1853(6):1528-39. DOI: 10.1016/j.bbamcr.2014.12.018. View

20.

Skrott Z, Cvek B . Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells. Mini Rev Med Chem. 2012; 12(12):1184-92. DOI: 10.2174/138955712802762068. View